Show an ad over header. AMP

Rich countries are taking the vaccine fast lane. Others could wait years

The vaccine breakthroughs from Pfizer and Modernaare incredible news, for a small sliver of the world.

The big picture: Wealthy countries like the U.S. have secured their access to those vaccines and others and are increasingly confident they'll begin mass vaccination this spring. But according to research from Duke University's Global Health Institute, there likely won't be enough doses to cover the entire global population until 2024.

Driving the news: Pfizer has agreed to sell at least 1.1 billion doses combined to the U.S., EU, Canada, Japan and U.K. That's nearly all of the 1.3 billion it aims to produce by the end of 2021.

  • Its vaccine also has to be stored at -80C, a requirement that few facilities in the developing world are equipped to handle.

Moderna's announcement today that its vaccine appears to be 95% effective should be better news for countries outside of the U.S. and Europe.

  • The storage requirements aren't as onerous and it's part of the COVAX portfolio of vaccines the World Health Organization and other groups plan to distribute to lower-income countries.
  • Tal Zaks, Moderna's chief medical officer, told the Axios Pro Rata podcast today that the 20 million doses it will produce this year will all go to the U.S., which helped fund the vaccine's development and has purchased at least 100 million doses in total.
llustration: Sarah Grillo/Axios
  • Moderna also has deals with the EU and Japan. After today's news prompted questions over why it hadn't invested in the Moderna vaccine, the U.K. government announced it was in "advanced talks" to ensure its access.
  • The flipside: "There is a dialogue ongoing with COVAX. I don't think we have quite aligned with them on how many doses and when those doses would be available for the COVAX collaboration," Zaks said.

What to watch: The best hope for a vaccine that will be quickly produced at scale for developing countries may lie with Oxford and AstraZeneca, which expect to release efficacy data for their vaccine by year's end.

  • That vaccine is also part of the COVAX portfolio and has a deal with the world's highest-capacity vaccine manufacturer, the Serum Institute of India.
  • The Serum Institute is slated to produce two-thirds of the doses promised to low- and middle-income countries by AstraZeneca, Johnson & Johnson, Novavax and Sanofi, per WaPo.

State of play: Canada has purchased enough doses to vaccinate its population five times over, according to the Duke study. It's one of several countries hedging their bets to ensure access even if some vaccines aren't approved.

  • Several middle-income countries have cut smaller-scale deals with pharmaceutical companies or vaccine-producing countries like China or Russia.
  • Brazil, Egypt and India are among those that expect to receive access because they have significant vaccine production capacity or are hosting clinical trials.
Data: Gavi, The Vaccine Alliance; Map: Naema Ahmed/Axios

Much of the rest of the world is relying on COVAX.

  • Wealthier countries will effectively subsidize access for poorer ones, with an initial wave of distribution intended to reach 3% of each country's population and a second wave bringing that to 20%, potentially by the end of 2021.

With its bulk orders for six vaccines, the U.S. could find itself in control of around one-quarter of the world's near-term supply, according to the Duke analysis.

Why it matters: "I think we're going to see the tension between vaccine nationalism and vaccine diplomacy, where deploying some of our surplus vaccine doses in a strategic way becomes part of the U.S. foreign policy," says Dr. Krishna Udayakumar, director of Duke's Global Health Innovation Center.

Illustration: Annelise Capossela/Axios

Joe Biden plans to re-engage with the WHO, though his team has not said whether he would participate in COVAX.

  • China is already promising access to its vaccines to friendly or neighboring countries.
  • Russia, meanwhile, has cut deals with several countries for access to its vaccine, which Vladimir Putin has used to emphasize Moscow's global clout.
  • There are now conversations underway to determine whether and how wealthy countries that purchased more doses than they ultimately need will be able to steer the surplus into COVAX, Udayakumar says.

The bottom line: Beyond the humanitarian and diplomatic considerations, it's also clear that the pandemic won't be over anywhere — as a public health crisis or as a drag on the global economy — until it's under control everywhere.

CDC: It's time for "universal face mask use"

The CDC is urging “universal face mask use” for the first time since the coronavirus pandemic began, citing recent case spikes as the U.S. has entered a phase of “high-level transmission” before winter officially begins.

Why it matters: Daily COVID-related deaths across the U.S. hit a new record on Wednesday. Face coverings have been shown to increase protection of the wearer and those around them, despite some Americans' reluctance to use them.

Keep reading... Show less

Saudi Arabia and Qatar near deal to end standoff, sources say

Saudi Arabia and Qatar are close to a deal to end the diplomatic crisis in the Gulf following U.S.-mediated reconciliation talks this week, sources familiar with the talks tell me.

Why it matters: Restoring relations between Saudi Arabia and Qatar would bring a sense of stability back to the Gulf after a 3.5 year standoff. It could also notch a last-minute achievement for the Trump administration before Jan. 20.

Keep reading... Show less

President of Soros foundation leaves amid speculation of potential Biden role

Patrick Gaspard, who served as ambassador to South Africa under President Barack Obama, is stepping down as president of George Soros' Open Society Foundations, fueling speculation that he'll join the Biden administration, potentially as Labor secretary.

What to know: Before his stint as ambassador, Gaspard was Obama's political director in the White House, drawing upon his experience in the labor movement to advance Obama's legislative agenda on health care and financial services reform.

Keep reading... Show less

House passes bill to decriminalize marijuana

The House on Friday voted 228-164 in favor of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, marking the first time a congressional chamber has voted in favor of decriminalizing marijuana at the federal level.

Why it matters: The Washington Post describes the bill as a "landmark retreat in the nation’s decades-long war on drugs," which has disproportionately affected people of color.

Keep reading... Show less

Clean trucks are paving the road to the electric vehicle era

The electric vehicle revolution is underway, led by the un-sexiest of plug-in models: the commercial truck.

Why it matters: Growing demand for cleaner trucks means 2021 will be a pivotal year for electric vehicles — just not the kind you might have expected.

Keep reading... Show less

Over 13 million people are receiving pandemic unemployment assistance expiring on Dec. 26

Data: Department of Labor; Chart: Axios Visuals

The number of people receiving unemployment benefits is falling but remains remarkably high three weeks before pandemic assistance programs are set to expire. More than 1 million people a week are still filing for initial jobless claims, including nearly 300,000 applying for pandemic assistance.

By the numbers: As of Nov. 14, 20.2 million Americans were receiving unemployment benefits of some kind, including more than 13.4 million on the Pandemic Unemployment Assistance (PUA) and Pandemic Emergency Unemployment Compensation (PEUC) programs that were created as part of the CARES Act and end on Dec. 26.

Keep reading... Show less

The top candidates Biden is considering for key energy and climate roles

Senate Minority Leader Chuck Schumer (D-N.Y.) has urged President-elect Joe Biden to nominate Mary Nichols, chair of California's air pollution regulator, to lead the Environmental Protection Agency, Bloomberg reports.

Why it matters: The reported push by Schumer could boost Nichol's chances of leading an agency that will play a pivotal role in Biden's vow to enact aggressive new climate policies — especially because the plan is likely to rest heavily on executive actions.

Keep reading... Show less

U.S. economy adds 245,000 jobs in November as rate of recovery slows

Axios Visuals. Bureau of Labor Statistics.

The U.S. economy added 245,000 jobs in November, while the unemployment rate fell to 6.7% from 6.9%, the government said on Friday.

Why it matters: The labor market continues to recover even as coronavirus cases surge— though it's still millions of jobs short of the pre-pandemic level. The problem is that the rate of recovery is slowing significantly.

This story is breaking news. Please check back for updates.



Get Goodhumans in your inbox

Most Read

More Stories